Optimizing Modifiable and Lifestyle-related Factors in the Prevention of Dementia Disorders with Special Reference to Alzheimer, Parkinson and Autism Diseases

Author(s): Umesh C. Gupta*, Subhas C. Gupta

Journal Name: Current Nutrition & Food Science

Volume 16 , Issue 6 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Dementia is a syndrome and an umbrella term that encompasses Alzheimer, Parkinson and autism diseases. These diseases are by far the most common cause of dementia; therefore this investigation will chiefly include these disorders, with a limited discussion of few other disorders related to dementia. Alzheimer’s disease (AD) is characterized by the accumulation of cerebral β-amyloid plaques, tau proteins and memory loss; Parkinson by the deterioration of brain cells which regulate the movement of body parts and produce dopamine; and autism by abnormalities of social disorder and difficulty in communicating and forming relationships. Alzheimer’s disease and cognitive impairment in dementia are age-related and manageable only with early diagnosis and prevention. Data based on several decades of research has shown that the major factors responsible for the induction of inflammation in dementia and many chronic diseases are infections, obesity, alcohol, radiation, environmental pollutants, improper nutrition, lack of physical activity, depression, anxiety, genetic factors, and sleep deprivation. There are some studied preventive measures for dementia including continued physical activity and consuming predominantly a plant-based Mediterranean diet comprising olive oil and foods containing flavonoids and other phytochemicals having strong antioxidant and anti-inflammatory properties and along with management of chronic conditions.

Keywords: Aging, curcumin, cystic fibrosis, disability, huntington, minerals, schizophrenia, sleep apnea.

[1]
Saint Elizabeth Health Care. How much do you know about dementia? Elizz Editor 2018 Available from: https://elizz.com/ caregiver-resources/caregiving-tips/how-much-do-you-know-about-dementia
[2]
Choe S, Cai M, Jerng UM, Lee JH. The efficacy and underlying mechanism of Moxibustion in preventing cognitive impairment: a systematic review of animal studies. Exp Neurobiol 2018; 27(1): 1-15.
[http://dx.doi.org/10.5607/en.2018.27.1.1] [PMID: 29535565]
[3]
Xu J, Wold EA, Ding Y, Shen Q, Zhou J. Therapeutic potential of oridonin and its analogs: from anticancer and anti-inflammation to neuroprotection. Molecules 2018; 23(2): 474.
[http://dx.doi.org/10.3390/molecules23020474]
[4]
Fu Y, Ma JF, Chen SD. Progress of the relationship between serum uric acid and neurodegenerative diseases. CJCNN 2018; 18(3): 204-12.
[5]
Andrade AG, Bubu OM, Varga AW, Osorio RS. The relationship between obstructive sleep apnea and Alzheimer’s disease. J Alzheimers Dis 2018; 64(s1): S255-70.
[http://dx.doi.org/10.3233/JAD-179936] [PMID: 29782319]
[6]
Smith AD, Refsum H, Bottiglieri T, et al. Homocysteine and dementia: an international consensus statement. J Alzheimers Dis 2018; 62(2): 561-70.
[http://dx.doi.org/10.3233/JAD-171042] [PMID: 29480200]
[7]
Hamlett ED, Ledreux A, Potter H, et al. Exosomal biomarkers in Down syndrome and Alzheimer’s disease. Free Radic Biol Med 2018; 114: 110-21.
[http://dx.doi.org/10.1016/j.freeradbiomed.2017.08.028] [PMID: 28882786]
[8]
Li BY, Xu W, Deng YL, et al. Progress of translational research on the diagnosis and treatment of Alzheimer’s disease and other dementias. CJCNN 2018; 18(2): 95-8.
[9]
Cummings J, Ritter A, Zhong K. Clinical trials for disease-modifying therapies in Alzheimer’s disease: a primer, lessons learned, and a blueprint for the future. J Alzheimers Dis 2018; 64(s1): S3-S22.
[http://dx.doi.org/10.3233/JAD-179901] [PMID: 29562511]
[10]
Baazaoui N, Iqbal K. A novel therapeutic approach to treat Alzheimer’s disease by neurotrophic support during the period of synaptic compensation. J Alzheimers Dis 2018; 62(3): 1211-8.
[http://dx.doi.org/10.3233/JAD-170839] [PMID: 29562539]
[11]
Alzheimer Alois – 2014 Neurologist, Scientist, PsychiatristBiography (1864-1915) Available from: https://www.biography. com/people/alois-alzheimer-21216461
[12]
Martins RN, Villemagne V, Sohrabi HR, et al. Alzheimer’s disease: a journey from amyloid peptides and oxidative stress, to biomarker technologies and disease prevention strategies-gains from AIBL and DIAN cohort studies. J Alzheimers Dis 2018; 62(3): 965-92.
[http://dx.doi.org/10.3233/JAD-171145] [PMID: 29562546]
[13]
Meiliana A, Dewi NM, Wijaya A. New insight in the molecular mechanisms of neurodegenerative disease. Indones Biomed J 2018; 10(1): 16-34.
[http://dx.doi.org/10.18585/inabj.v10i1.448]
[14]
Pantel J. [Alzheimer’s disease from Auguste Deter to the present : progress, disappointments and open questions]. Z Gerontol Geriatr 2017; 50(7): 576-87.
[http://dx.doi.org/10.1007/s00391-017-1307-2] [PMID: 28924872]
[15]
Konijnenberg E, Carter SF, Ten Kate M, et al. The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimers Res Ther 2018; 10(1): 75.
[http://dx.doi.org/10.1186/s13195-018-0406-7] [PMID: 30075734]
[16]
Palmano K, Rowan A, Guillermo R, Guan J, McJarrow P. The role of gangliosides in neurodevelopment. Nutrients 2015; 7(5): 3891-913.
[http://dx.doi.org/10.3390/nu7053891] [PMID: 26007338]
[17]
Jazvinšćak Jembrek M, Slade N, Hof PR, Šimić G. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer’s disease. Prog Neurobiol 2018; 168: 104-27.
[http://dx.doi.org/10.1016/j.pneurobio.2018.05.001] [PMID: 29733887]
[18]
Pérez-Gálvez A, Jarén-Galán M, Garrido-Fernández J, Calvo MV, Visioli F, Fontecha J. Activities, bioavailability, and metabolism of lipids from structural membranes and oils: promising research on mild cognitive impairment. Pharmacol Res 2018; 134: 299-304.
[http://dx.doi.org/10.1016/j.phrs.2018.07.013] [PMID: 30016644]
[19]
Rege SD, Geetha T, Broderick TL, Babu JR. Can diet and physical activity limit Alzheimer’s disease risk? Curr Alzheimer Res 2017; 14(1): 76-93.
[http://dx.doi.org/10.2174/1567205013666160314145700] [PMID: 26971938]
[20]
Han JY, Han SH. Primary prevention of Alzheimer’s disease: is it an attainable goal? J Korean Med Sci 2014; 29(7): 886-92.
[http://dx.doi.org/10.3346/jkms.2014.29.7.886] [PMID: 25045219]
[21]
Jaworski M. Mitigate the effects of cognitive by appropriate diet for people affected by Alzheimer’s disease. Neuropsychiatr Neuropsychologia 2010; 5(3-4): 141-8.
[22]
Lai AY, McLaurin J. Rho-associated protein kinases as therapeutic targets for both vascular and parenchymal pathologies in Alzheimer’s disease. J Neurochem 2018; 144(5): 659-68.
[http://dx.doi.org/10.1111/jnc.14130] [PMID: 28722749]
[23]
Panza F, Seripa D, Solfrizzi V, et al. Targeting cognitive frailty: clinical and neurobiological roadmap for a single complex phenotype. J Alzheimers Dis 2015; 47(4): 793-813.
[http://dx.doi.org/10.3233/JAD-150358] [PMID: 26401761]
[24]
Secher M, Gillette-Guyonnet S, Nourhashemi F. Nutrition and Alzheimer’s disease. Nutr Clin Metab 2011; 25(4): 227-32.
[http://dx.doi.org/10.1016/j.nupar.2011.09.004]
[25]
Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta 2013; 1830(6): 3670-95.
[http://dx.doi.org/10.1016/j.bbagen.2013.02.008] [PMID: 23428572]
[26]
Elahi FM, Miller BL. A clinicopathological approach to the diagnosis of dementia. Nat Rev Neurol 2017; 13(8): 457-76.
[http://dx.doi.org/10.1038/nrneurol.2017.96] [PMID: 28708131]
[27]
Tanzi REA. A brief history of Alzheimer’s disease gene discovery. J Alzheimers Dis 2013; 33(Suppl. 1): S5-S13.
[http://dx.doi.org/10.3233/JAD-2012-129044] [PMID: 22986781]
[28]
Borchelt DR. Targeting the accomplice to thwart the culprit: a new target for the prevention of amyloid deposition. J Clin Invest 2018; 128(5): 1734-6.
[http://dx.doi.org/10.1172/JCI120414] [PMID: 29600962]
[29]
Dubois B, Hampel H, Feldman HH, et al. Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer’s Association on “The Preclinical State of AD”; July 23, 2015; Washington DC, USA. Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement 2016; 12(3): 292-323.
[http://dx.doi.org/10.1016/j.jalz.2016.02.002] [PMID: 27012484]
[30]
Khachaturian ZS, Khachaturian AS. Politics of science: Progress toward prevention of the dementia-Alzheimer’s syndrome. Mol Aspects Med 2015; 43-44: 3-15.
[http://dx.doi.org/10.1016/j.mam.2015.06.001] [PMID: 26054567]
[31]
van Wijk N, Broersen LM, de Wilde MC, et al. Targeting synaptic dysfunction in Alzheimer’s disease by administering a specific nutrient combination. J Alzheimers Dis 2014; 38(3): 459-79.
[http://dx.doi.org/10.3233/JAD-130998] [PMID: 23985420]
[32]
Abbatecola AM, Russo M, Barbieri M. Dietary patterns and cognition in older persons. Curr Opin Clin Nutr Metab Care 2018; 21(1): 10-3.
[http://dx.doi.org/10.1097/MCO.0000000000000434] [PMID: 29035971]
[33]
Ano Y, Nakayama H. Preventive effects of dairy products on dementia and the underlying mechanisms. Intern J Mol Sci 2018; 19(7): 1927.
[http://dx.doi.org/10.3390/ijms19071927]
[34]
Grayson SE, Muscoplat CC. The vitamin hype includes some hazards the history of vitamin use and abuse. Agro Food Ind Hi-Tech 2015; 26(5): 28-31.
[35]
Hunter S, Brayne C. Integrating the molecular and the population approaches to dementia research to help guide the future development of appropriate therapeutics. Biochem Pharmacol 2014; 88(4): 652-60.
[http://dx.doi.org/10.1016/j.bcp.2013.12.015] [PMID: 24389044]
[36]
Cascella M, Bimonte S, Barbieri A, et al. Dissecting the potential roles of Nigella sativa and its constituent thymoquinone on the prevention and on the progression of Alzheimer’s disease. Front Aging Neurosci 2018; 10: 16.
[http://dx.doi.org/10.3389/fnagi.2018.00016] [PMID: 29479315]
[37]
Chen M, Du ZY, Zheng X, Li DL, Zhou RP, Zhang K. Use of curcumin in diagnosis, prevention, and treatment of Alzheimer’s disease. Neural Regen Res 2018; 13(4): 742-52.
[http://dx.doi.org/10.4103/1673-5374.230303] [PMID: 29722330]
[38]
Momtaz S, Hassani S, Khan F, Ziaee M, Abdollahi M. Cinnamon, a promising prospect towards Alzheimer’s disease. Pharmacol Res 2018; 130: 241-58.
[http://dx.doi.org/10.1016/j.phrs.2017.12.011] [PMID: 29258915]
[39]
Navarro G, Martínez Pinilla E, Ortiz R, Noé V, Ciudad CJ, Franco R. Resveratrol and related stilbenoids, nutraceutical/dietary complements with health-promoting actions: industrial production, safety, and the search for mode of action. Compr Rev Food Sci Food Saf 2018; 17(4): 808-26.
[http://dx.doi.org/10.1111/1541-4337.12359]
[40]
Shehzad A, Parveen S, Qureshi M, Subhan F, Lee YS. Decursin and decursinol angelate: molecular mechanism and therapeutic potential in inflammatory diseases. Inflamm Res 2018; 67(3): 209-18.
[http://dx.doi.org/10.1007/s00011-017-1114-7] [PMID: 29134229]
[41]
Stárka L. The origin of 7α-hydroxy-dehydroepiandrosterone and its physiological role: a history of discoveries. Physiol Res 2017; 66(3)(Suppl. 3): S285-94.
[http://dx.doi.org/10.33549/physiolres.933717] [PMID: 28948812]
[42]
Weiser MJ, Butt CM, Mohajeri MH. Docosahexaenoic acid and cognition throughout the lifespan. Nutrients 2016; 8(2): 99.
[http://dx.doi.org/10.3390/nu8020099] [PMID: 26901223]
[43]
Yaqoob P, Shaikh SR. The nutritional and clinical significance of lipid rafts. Curr Opin Clin Nutr Metab Care 2010; 13(2): 156-66.
[http://dx.doi.org/10.1097/MCO.0b013e328335725b] [PMID: 20010096]
[44]
Fiala M. Re-balancing of inflammation and abeta immunity as a therapeutic for Alzheimer’s disease-view from the bedside. CNS Neurol Disord Drug Targets 2010; 9(2): 192-6.
[http://dx.doi.org/10.2174/187152710791012044] [PMID: 20205641]
[45]
Li YR, Li S, Lin CC. Effect of resveratrol and pterostilbene on aging and longevity. Biofactors 2018; 44(1): 69-82.
[http://dx.doi.org/10.1002/biof.1400] [PMID: 29210129]
[46]
Serra D, Almeida LM, Dinis TCP. Dietary polyphenols: a novel strategy to modulate microbiota-gut-brain axis. Trends Food Sci Technol 2018; (78): 224-33.
[http://dx.doi.org/10.1016/j.tifs.2018.06.007]
[47]
Butler M, McCreedy E, Nelson VA, et al. Does cognitive training prevent cognitive decline? Ann Intern Med 2018; 168(1): 63-8.
[http://dx.doi.org/10.7326/M17-1531] [PMID: 29255842]
[48]
Chételat G, Lutz A, Arenaza-Urquijo E, Collette F, Klimecki O, Marchant N. Why could meditation practice help promote mental health and well-being in aging? Azheimers Res Ther 2018; 10(1): 204-12.
[49]
Aridi YS, Walker JL, Wright ORL. The association between the Mediterranean dietary pattern and cognitive health: a systematic review. Nutrients 2017; 9(7);E674,
[http://dx.doi.org/10.3390/nu9070674] [PMID: 28657600]
[50]
Charoenprasert S, Mitchell A. Factors influencing phenolic compounds in table olives (Olea europaea). J Agric Food Chem 2012; 60(29): 7081-95.
[http://dx.doi.org/10.1021/jf3017699] [PMID: 22720792]
[51]
Féart C, Samieri C, Barberger-Gateau P. Mediterranean diet and cognitive function in older adults. Curr Opin Clin Nutr Metab Care 2010; 13(1): 14-8.
[http://dx.doi.org/10.1097/MCO.0b013e3283331fe4] [PMID: 19834324]
[52]
Dominguez LJ, Barbagallo M. Nutritional prevention of cognitive decline and dementia. Acta Biomed 2018; 89(2): 276-90.
[PMID: 29957766]
[53]
Yannakoulia M, Kontogianni M, Scarmeas N. Cognitive health and Mediterranean diet: just diet or lifestyle pattern? Ageing Res Rev 2015; 20: 74-8.
[http://dx.doi.org/10.1016/j.arr.2014.10.003] [PMID: 25461244]
[54]
Johnson SC, Koscik RL, Jonaitis EM, et al. The Wisconsin registry for Alzheimer’s prevention: a review of findings and current directions. Alzheimers Dement (Amst) 2017; 10: 130-42.
[http://dx.doi.org/10.1016/j.dadm.2017.11.007] [PMID: 29322089]
[55]
Dauncey MJ. Nutrition, the brain and cognitive decline: insights from epigenetics. Eur J Clin Nutr 2014; 68(11): 1179-85.
[http://dx.doi.org/10.1038/ejcn.2014.173] [PMID: 25182020]
[56]
Chasapis CT, Loutsidou AC, Spiliopoulou CA, Stefanidou ME. Zinc and human health: an update. Arch Toxicol 2012; 86(4): 521-34.
[http://dx.doi.org/10.1007/s00204-011-0775-1] [PMID: 22071549]
[57]
Du K, Liu M, Pan Y, Zhong X, Wei M. Association of serum manganese levels with Alzheimer’s disease and mild cognitive impairment: A systematic review and meta-analysis. Nutrients 2017; 10(3): 231.
[http://dx.doi.org/10.3390/nu9030231]
[58]
Kirkland AE, Sarlo GL, Holton KF. The role of magnesium in neurological disorders. Nutrients 2018; 10(6):E730.
[http://dx.doi.org/10.3390/nu10060730] [PMID: 29882776]
[59]
Mandel SA, Amit T, Weinreb O, Youdim MBH. Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases. J Alzheimers Dis 2011; 25(2): 187-208.
[http://dx.doi.org/10.3233/JAD-2011-101803] [PMID: 21368374]
[60]
Moreira PL, Villas Boas PJ, Ferreira ALA. Association between oxidative stress and nutritional status in the elderly. Rev Assoc Med Bras 2014; 60(1): 75-83.
[61]
Rijpma A, Meulenbroek O, Olde Rikkert MGM. Cholinesterase inhibitors and add-on nutritional supplements in Alzheimer’s disease: a systematic review of randomized controlled trials. Ageing Res Rev 2014; 16(1): 105-12.
[http://dx.doi.org/10.1016/j.arr.2014.06.002] [PMID: 24982004]
[62]
Spence J, Chintapenta M, Kwon HI, Blaszczyk AT. A brief review of three common supplements used in Alzheimer’s disease. Consult Pharm 2017; 32(7): 412-4.
[http://dx.doi.org/10.4140/TCP.n.2017.412] [PMID: 28701253]
[63]
Jaafaru MS, Abd Karim NA, Enas ME, Rollin P, Mazzon E, Abdull Razis AF. Protective effect of glucosinolates hydrolytic products in neurodegenerative diseases (NDDs). Nutrients 2018; 10(5): 580.
[64]
Bachurin SO, Gavrilova SI, Samsonova A, Barreto GE, Aliev G. Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention. Pharmacol Res 2018; 129: 216-26.
[http://dx.doi.org/10.1016/j.phrs.2017.11.021] [PMID: 29170097]
[65]
Hanyu H. Prevention of dementia-with special reference to lifestyle and vascular risk factors. Brain Nerve 2018; 70(3): 191-8.
[PMID: 29519962]
[66]
Wikipedia. History of Parkinson’s disease The free encyclopedia 2018 Available from: https://en.wikipedia.org/wiki/History_of_Parkinson%27s_disease
[67]
Paul SS, Dibble LE, Peterson DS. Motor learning in people with Parkinson’s disease: implications for fall prevention across the disease spectrum. Gait Posture 2018; 61: 311-9.
[http://dx.doi.org/10.1016/j.gaitpost.2018.01.026] [PMID: 29413803]
[68]
Tana C, Lauretani F, Ticinesi A, Prati B, Nouvenne A, Meschi T. Molecular and clinical issues about the risk of venous thromboembolism in older patients: a focus on Parkinson’s disease and Parkinsonism. Int J Mol Sci 2018; 19(5);E1299.
[http://dx.doi.org/10.3390/ijms19051299] [PMID: 29701703]
[69]
Wang G, Cui HL, Liu J, et al. Progress of translational research on the pathogenesis, diagnosis and treatment of Parkinson’s disease. CJCNN 2018; 18(1): 19-24.
[70]
Jung UJ, Kim SR. Beneficial effects of flavonoids against Parkinson’s disease. J Med Food 2018; 21(5): 421-32.
[http://dx.doi.org/10.1089/jmf.2017.4078] [PMID: 29412767]
[71]
Lanza K, Bishop C. Serotonergic targets for the treatment of L-DOPA-induced dyskinesia. J Neural Transm (Vienna) 2018; 125(8): 1203-16.
[http://dx.doi.org/10.1007/s00702-017-1837-1] [PMID: 29305656]
[72]
Lee SH, Suk K. Identification of glia phenotype modulators based on select glial function regulatory signaling pathways. Expert Opin Drug Discov 2018; 13(7): 627-41.
[http://dx.doi.org/10.1080/17460441.2018.1465925] [PMID: 29676181]
[73]
Marinus J, Zhu K, Marras C, Aarsland D, van Hilten JJ. Risk factors for non-motor symptoms in Parkinson’s disease. Lancet Neurol 2018; 17(6): 559-68.
[http://dx.doi.org/10.1016/S1474-4422(18)30127-3] [PMID: 29699914]
[74]
Parvez MK. Natural or plant products for the treatment of neurological disorders: current knowledge. Curr Drug Metab 2018; 19(5): 424-8.
[http://dx.doi.org/10.2174/1389200218666170710190249] [PMID: 28699506]
[75]
Nirmala C, Bisht MS, Bajwa HK, Santosh O. Bamboo: a rich source of natural antioxidants and its applications in the food and pharmaceutical industry. Trends Food Sci Technol 2018; 77: 91-9.
[http://dx.doi.org/10.1016/j.tifs.2018.05.003]
[76]
Ellwanger JH, Franke SIR, Bordin DL, Prá D, Henriques JAP. Biological functions of selenium and its potential influence on Parkinson’s disease. An Acad Bras Cienc 2016; 88(3)(Suppl.): 1655-74.
[http://dx.doi.org/10.1590/0001-3765201620150595] [PMID: 27556332]
[77]
Ruan Q, Ruan J, Zhang W, Qian F, Yu Z. Targeting NAD+ degradation: the therapeutic potential of flavonoids for Alzheimer’s disease and cognitive frailty. Pharmacol Res 2018; 128: 345-58.
[http://dx.doi.org/10.1016/j.phrs.2017.08.010] [PMID: 28847709]
[78]
Szwajgier D, Baranowska-Wójcik E, Borowiec K. Phenolic acids exert anticholinesterase and cognition-improving effects. Curr Alzheimer Res 2018; 15(6): 531-43.
[http://dx.doi.org/10.2174/1567205014666171128102557] [PMID: 29189157]
[79]
Zheng M, Xin Y, Li Y, et al. Ginsenosides: a potential neuroprotective agent. BioMed Res Int 2018; 2018:8174345.
[80]
Vinholes J, Silva BM, Silva LR. Hydroxycinnamic acids (HCAS): structure, biological properties and health effects. Adv Med Biol 2015; (88): 105-30.
[81]
Stavroulakis T, McDermott CJ. Enteral feeding in neurological disorders. Pract Neurol 2016; 16(5): 352-61.
[http://dx.doi.org/10.1136/practneurol-2016-001408] [PMID: 27152026]
[82]
Lilamand M, Hennequin V, Raynaud-Simon A. Nutrition in structured care plans for the elderly. Nutr Clin Metab 2016; 30(4): 340-6.
[http://dx.doi.org/10.1016/j.nupar.2016.11.002]
[83]
Mischley LK, Leverenz JB, Lau RC, et al. A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson’s disease. Mov Disord 2015; 30(12): 1696-701.
[http://dx.doi.org/10.1002/mds.26351] [PMID: 26230671]
[84]
Shapira AL, Handzel R, Korczyn AD. The lived experience of Parkinson’s disease: A content analysis of parkinson’s patients’ blogs. Isr Med Assoc J 2017; 19(11): 685-90.
[PMID: 29185282]
[85]
Fuhrman J. Heart-brain connection: fitness now protects your brain in your 70s and 80s Stay fit today; avoid dementia tomorrow 2018 Available from: https://www.drfuhrman.com/library/eat-to-live-blog/156/heart-brain-connection-fitness-now-protects-your-brain-in-your-70s-and-80s
[86]
Fang X, Han D, Chang Q, Min J, Wang F. Associations of levels of physical with risk of Parkinson disease A systematic review of meta-analysis JAMA 2018; 1(5): 182421
[87]
CDC. Autism Society of America Types of autism Autism Support of West Shore 2014 Available from: https://www.asws.org/WhatisAutism.aspx
[88]
What is Autism? Medical News Today 2018 Available from: https://www.medicalnewstoday.com/articles/323758.php
[89]
Ali A, Cui X, Eyles D. Developmental vitamin D deficiency and autism: putative pathogenic mechanisms. J Steroid Biochem Mol Biol 2018; 175: 108-18.
[http://dx.doi.org/10.1016/j.jsbmb.2016.12.018] [PMID: 28027915]
[90]
Shamberger RJ. Autism rates associated with nutrition and the WIC program. J Am Coll Nutr 2011; 30(5): 348-53.
[http://dx.doi.org/10.1080/07315724.2011.10719978] [PMID: 22081621]
[91]
van De Sande MMH, van Buul VJ, Brouns FJPH. Autism and nutrition: the role of the gut-brain axis. Nutr Res Rev 2014; 27(2): 199-214.
[http://dx.doi.org/10.1017/S0954422414000110] [PMID: 25004237]
[92]
What does the word autism mean? History of autism. Available from:https://www.webmed.com/brain/autism/what-does-autism-mean
[93]
Fisch GS. Nosology and epidemiology in autism: classification counts Am J Med Genet Part C Semin Med Genet 2012; (2): 91- 103
[94]
Borovac J, Bosch M, Okamoto K. Regulation of actin dynamics during structural plasticity of dendritic spines: signaling messengers and actin-binding proteins. Mol Cell Neurosci 2018; 91: 122-30.
[http://dx.doi.org/10.1016/j.mcn.2018.07.001] [PMID: 30004015]
[95]
Arnold GL, Hyman SL, Mooney RA, Kirby RS. Plasma amino acids profiles in children with autism: potential risk of nutritional deficiencies. J Autism Dev Disord 2003; 33(4): 449-54.
[http://dx.doi.org/10.1023/A:1025071014191] [PMID: 12959424]
[96]
Rybakowski F, Białek A, Chojnicka I, et al. [Autism spectrum disorders - epidemiology, symptoms, comorbidity and diagnosis]. Psychiatr Pol 2014; 48(4): 653-65.
[PMID: 25314794]
[97]
Piskorz-Ogórek K, Ogórek S, Cies̈lińska A, Kostyra E. Autism in Poland in comparison to other countries. Pol Ann Med 2015; 22(1): 35-40.
[http://dx.doi.org/10.1016/j.poamed.2015.03.010]
[98]
Whyatt CP, Torres EB. Autism research: An objective quantitative review of progress and focus between 1994 and 2015. Front Psychol 2018; 9(AUG). Front Psychol 2018; 9: 1526.
[http://dx.doi.org/10.3389/fpsyg.2018.01526] [PMID: 30190695]
[99]
Fujiwara T, Morisaki N, Honda Y, Sampei M, Tani Y. Chemicals, nutrition, and autism spectrum disorder: a mini-review. Front Neurosci 2016; 10: 174.
[100]
James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004; 80(6): 1611-7.
[http://dx.doi.org/10.1093/ajcn/80.6.1611] [PMID: 15585776]
[101]
Józefczuk J, Kasprzycka W, Czarnecki R, et al. Homocysteine as a diagnostic and etiopathogenic factor in children with autism spectrum disorder. J Med Food 2017; 20(8): 744-9.
[http://dx.doi.org/10.1089/jmf.2016.0150] [PMID: 28598237]
[102]
Neumeyer AM, Cano Sokoloff N, McDonnell EI, et al. Nutrition and bone density in boys with autism spectrum disorder. J Acad Nutr Diet 2018; 118(5): 865-77.
[http://dx.doi.org/10.1016/j.jand.2017.11.006] [PMID: 29409733]
[103]
Dickerson AS, Rahbar MH, Bakian AV, et al. Autism spectrum disorder prevalence and associations with air concentrations of lead, mercury, and arsenic. Environ Monit Assess 2016; 188(7): 407.
[http://dx.doi.org/10.1007/s10661-016-5405-1] [PMID: 27301968]
[104]
Al-Ayadhi L, Halepoto DM. Role of proteomics in the discovery of autism biomarkers. J Coll Physicians Surg Pak 2013; 23(2): 137-43.
[PMID: 23374519]
[105]
Davidson M. Vaccination as a cause of autism-myths and controversies. Dialogues Clin Neurosci 2017; 19(4): 403-7.
[PMID: 29398935]
[106]
Sears JC, Broadie K. Fragile X mental retardation protein regulates activity-dependent membrane trafficking and trans-synaptic signaling mediating synaptic remodeling. Front Mole Neurosci 2018; p. 10.
[107]
Ilieva M, Fex Svenningsen Å, Thorsen M, Michel TM. Psychiatry in a dish: stem cells and brain organoids modeling autism spectrum disorders. Biol Psychiatry 2018; 83(7): 558-68.
[http://dx.doi.org/10.1016/j.biopsych.2017.11.011] [PMID: 29295738]
[108]
Máčová L, Bičíková M, Ostatníková D, Hill M, Stárka L, Vitamin D. Vitamin D, neurosteroids and autism. Physiol Res 2017; 66(Suppl. 3): S333-40.
[http://dx.doi.org/10.33549/physiolres.933721] [PMID: 28948817]
[109]
Berridge MJ. Vitamin D deficiency: infertility and neurodevelopmental diseases (attention deficit hyperactivity disorder, autism, and schizophrenia). Am J Physiol Cell Physiol 2018; 314(2): C135-51.
[http://dx.doi.org/10.1152/ajpcell.00188.2017] [PMID: 29070492]
[110]
Brito A, Russo FB, Muotri AR, Beltrão-Braga PCB. Autism spectrum disorders and disease modeling using stem cells. Cell Tissue Res 2018; 371(1): 153-60.
[http://dx.doi.org/10.1007/s00441-017-2685-x] [PMID: 28918504]
[111]
Cristiano C, Lama A, Lembo F, Mollica MP, Calignano A, Mattace Raso G. Interplay between peripheral and central inflammation in autism spectrum disorders: possible nutritional and therapeutic strategies. Front Physiol 2018; 9: 184.
[http://dx.doi.org/10.3389/fphys.2018.00184] [PMID: 29563885]
[112]
Shamberger RJ. Autism associated with B-vitamin deficiency linked to sugar intake and alcohol consumption. J Intellect Disabil Diagn Treat 2015; 3(1): 7-12.
[http://dx.doi.org/10.6000/2292-2598.2015.03.01.2]
[113]
Kirsten TB, Chaves-Kirsten GP, Bernardes S, et al. Lipopolysaccharide exposure induces maternal hypozincemia, and prenatall zinc treatment prevents autistic-like behaviors and disturbances in the striatal dopaminergic and mTOR systems of offspring. PLoS One 2015; 10(7)e0134565
[http://dx.doi.org/10.1371/journal.pone.0134565] [PMID: 26218250]
[114]
Kirsten TB, Queiroz-Hazarbassanov N, Bernardi MM, Felicio LF. Prenatal zinc prevents communication impairments and BDNF disturbance in a rat model of autism induced by prenatal lipopolysaccharide exposure. Life Sci 2015; 130(130): 12-7.
[http://dx.doi.org/10.1016/j.lfs.2015.02.027] [PMID: 25817235]
[115]
Spielman LJ, Gibson DL, Klegeris A. Unhealthy gut, unhealthy brain: The role of the intestinal microbiota in neurodegenerative diseases. Neurochem Int 2018; 120: 149-63.
[http://dx.doi.org/10.1016/j.neuint.2018.08.005] [PMID: 30114473]
[116]
Berding K, Donovan SM. Microbiome and nutrition in autism spectrum disorder: current knowledge and research needs. Nutr Rev 2016; 74(12): 723-36.
[http://dx.doi.org/10.1093/nutrit/nuw048] [PMID: 27864534]
[117]
Malhi P, Venkatesh L, Bharti B, Singhi P. Feeding problems and nutrient intake in children with and without autism: a comparative study. Indian J Pediatr 2017; 84(4): 283-8.
[http://dx.doi.org/10.1007/s12098-016-2285-x] [PMID: 28078576]
[118]
Duff J. Nutrition for ADHD and Autism. In: Cantor DS, Evans JR, Eds Clinical Neurotherapy. Cambridge, MA: Academic Press 2013; pp. 357-81.
[119]
Barnhill K, Gutierrez A, Ghossainy M, et al. Dietary status and nutrient intake of children with autism spectrum disorder: a case-control study. Res Autism Spectr Disord 2018; 50: 51-9.
[http://dx.doi.org/10.1016/j.rasd.2018.03.002]
[120]
Hertz-Picciotto I, Schmidt RJ, Krakowiak P. Understanding environmental contributions to autism: Causal concepts and the state of science. Autism Res 2018; 11(4): 554-86.
[http://dx.doi.org/10.1002/aur.1938] [PMID: 29573218]
[121]
Cannell JJ. Vitamin D and autism, what’s new? Rev Endocr Metab Disord 2017; 18(2): 183-93.
[http://dx.doi.org/10.1007/s11154-017-9409-0] [PMID: 28217829]
[122]
Gao L, Xi QQ, Wu J, et al. Association between prenatal environmental factors and child autism: a case control study in Tianjin, China. Biomed Environ Sci 2015; 28(9): 642-50.
[PMID: 26464251]
[123]
What is ALS, ALS CANADA? 2018 Available from: https://www. als.ca/about-als/what-is-als/
[126]
Cystic fibrosis – From Wikipedia, the free encyclopedia Available from: https://en.wikipedia.org/wiki/Cystic_fibrosis
[127]
Huntington disease – Genetics Home Reference – NIH. US National Library of Medicine Available from: https://ghr.nlm.nih.gov/ condition/huntington-disease
[128]
] History of Huntington’s disease (HD)? Huntington’s disease Available from: en.wikipedia.org
[129]
Mayo Clinic. Muscular Dystrophy Patients Care and Health Information Available from: https://www.mayoclinic.org/diseases-conditions/muscular-dystro phy/symptoms-causes/syc-20375388
[130]
[131]
Burton N. A Brief History of Schizophrenia through the ages Schizophrenia Available from: https://www.psychologytoday.com/us/ blog/hide-and-seek/201209/
[132]
Schizophrenia Overview. National Institute of Medical HealthAvailable from: https://www.nimh.nih.gov/health/topics/schizophre nia/index.shtml
[133]
Alford S, Patel D, Perakakis N, Mantzoros CS. Obesity as a risk factor for Alzheimer’s disease: weighing the evidence. Obes Rev 2018; 19(2): 269-80.
[http://dx.doi.org/10.1111/obr.12629] [PMID: 29024348]
[134]
Lu DP, Lu GP. An historical review and perspective on the impact of acupuncture on U.S. medicine and society. Med Acupunct 2013; 25(5): 311-6.
[http://dx.doi.org/10.1089/acu.2012.0921] [PMID: 24761180]
[135]
Daviglus ML, Bell CC, Berrettini W, et al. NIH state-of-the-science conference statement: Preventing Alzheimer’s disease and cognitive decline. NIH Consens State Sci Statements 2010; 27(4): 1-30.
[PMID: 20445638]
[136]
Wallace LMK, Theou O, Godin J, Andrew MK, Bennett DA, Rockwood K. Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer’s disease: a cross-sectional analysis of data from the Rush Memory and Aging Project. Lancet Neurol 2019; 18(2): 177-84.
[http://dx.doi.org/10.1016/S1474-4422(18)30371-5] [PMID: 30663607]
[137]
Garre-Olmo J. [Epidemiology of Alzheimer’s disease and other dementias]. Rev Neurol 2018; 66(11): 377-86.
[PMID: 29790571]
[138]
Wimo A. The end of the beginning of the Alzheimer’s disease nightmare: a devil’s advocate’s view. J Alzheimers Dis 2018; 64(s1): S41-6.
[http://dx.doi.org/10.3233/JAD-179905] [PMID: 29710714]
[139]
Baladia E, Pérez-Surio AF, Martínez-Rodríguez R. Summary of evidence-based nutritional recommendations of the clinical practice guideline for the management of patients with Parkinson’s disease. Nutr Hosp 2016; 33(3): 749-60.
[PMID: 27513514]
[140]
Carpenter LA, Boan AD, Wahlquist AE, et al. Screening and direct assessment methodology to determine the prevalence of autism spectrum disorders. Ann Epidemiol 2016; 26(6): 395-400.
[http://dx.doi.org/10.1016/j.annepidem.2016.04.003] [PMID: 27230493]
[141]
Sabayan B, Sorond F. Reducing risk of dementia in older ages. JAMA 2017; 317(19): 2028.
[http://dx.doi.org/10.1001/jama.2017.2247] [PMID: 28510681]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 6
Year: 2020
Page: [900 - 911]
Pages: 12
DOI: 10.2174/1573401315666190801120306
Price: $65

Article Metrics

PDF: 12
HTML: 2
EPUB: 1
PRC: 1